The healthcare provider prescribes enoxaparin sodium 80 mg subcutaneously twice daily. The nurse is preparing a preloaded 1 mL syringe labeled, 'enoxaparin sodium injection, USP 60 mg/0.6 mL'. How many mL should the nurse administer?

(Enter numeric value only. If rounding is required, round to the nearest tenth.)

Choice A reason: Storing unused vials at room temperature is incorrect information that indicates a need for further education by the nurse, because somatropin is a growth hormone that should be stored in the refrigerator (2°C to 8°C) until use. Exposure to heat or light can degrade the medication and reduce its effectiveness.

Choice B reason: Rotating injection sites to minimize discomfort is correct information that does not indicate a need for further education by the nurse, because somatropin is administered subcutaneously and repeated injections at the same site can cause skin irritation, bruising, or infection.

Choice C reason: Discarding the medication if the solution is cloudy is correct information that does not indicate a need for further education by the nurse, because somatropin is a clear and colorless solution that should not be used if it appears cloudy, discolored, or contains particles. This may indicate contamination or degradation of the medication.

Choice D reason: Administering the medication subcutaneously is correct information that does not indicate a need for further education by the nurse, because somatropin is a growth hormone that is given by subcutaneous injection using a syringe or a pen device. Subcutaneous injection allows for better absorption and bioavailability of the medication.

Choice A reason: Depression screening is not directly related to the effectiveness of orlistat, which is a medication that blocks the absorption of fat from the diet and helps to reduce weight. Depression screening may be important for the overall mental health of the client, but it is not an ongoing assessment for orlistat.

Choice B reason: Body mass index (BMI) is a measure of body fat based on height and weight, and it is used to assess the risk of obesity-related health problems. BMI is an ongoing assessment for orlistat, because it can indicate the progress and outcome of the weight management program. The goal of orlistat therapy is to achieve and maintain a healthy BMI.

Choice C reason: Daily calorie count is not an ongoing assessment for orlistat, because it does not reflect the amount of fat absorbed by the body. Orlistat works by blocking the action of lipase, an enzyme that breaks down fat in the intestine. Therefore, even if the client consumes a high-calorie diet, orlistat can prevent some of the fat from being absorbed and reduce weight. However, daily calorie count may be useful for monitoring the overall nutritional intake and energy balance of the client.

Choice D reason: Serum protein levels are not an ongoing assessment for orlistat, because they are not affected by the medication. Orlistat only blocks the absorption of fat, not protein or carbohydrates. Serum protein levels may be important for evaluating the nutritional status and organ function of the client, but they are not an indicator of orlistat effectiveness.